Sam Chun Dang Pharm Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
00:56
Jun 17
Jun 17
Contrarian biotech play against rate consensus
The market has overwhelmingly priced in higher interest rates, but oil prices may stay elevated and rate hikes may not be as severe. This creates a contrarian opportunity in beaten-down Korean biotech stocks. Year-end outlook for biotech and cosmetics is constructive, and it is time to start accumulating names like Alteogen, ABL Bio, LigaChem Bio, Sam Chun Dang Pharm, and DND Pharm rather than chasing momentum elsewhere.
MED
11:19
Apr 22
Apr 22
Avoid Sam Chun Dang until FDA clarity.
Sam Chun Dang Pharm has unresolved FDA approval and efficacy doubts after its sharp fall. The stock is not a falling knife to catch; wait for the issues to be resolved and consider cutting losses, as it can drag down the whole bio sector.
HIGH
02:40
Apr 10
Apr 10
ETF outflows weigh on Sam Chun Dang.
Sam Chun Dang Pharm is under pressure as ETF money is being withdrawn and the share price has fallen below KRW 500,000. The trust shock is also dragging on KOSDAQ sentiment.
MED
00:36
Apr 08
Apr 08
Sam Chun Dang needs trust recovery
Sam Chun Dang Pharm has plunged on audit and accounting trust issues, hurting the broader bio sector. It can rebound only if the company clears those doubts and proves SPS product sales, similar to how Celltrion eventually overcame accounting concerns with biosimilar sales. The price is near pre-rally levels, making it a name to monitor.
MED
00:57
Apr 06
Apr 06
Sam Chun Dang sale cancellation supports stock.
Sam Chun Dang Pharm rebounded after the CEO canceled a planned 250 billion won share sale, which had been pressuring the stock. With the overhang removed, the shares are recovering.
MED
08:14
Feb 09
Feb 09
Sam Chun Dang Pharm offers breakout potential.
Lee said Sam Chun Dang Pharm carries higher difficulty/risk than other pharma names, but its earnings momentum and margin expansion are powerful. After a sharp January rise, a February correction or rest period would be an attractive entry point, and he expected another high breakout.
MED
00:47
Feb 05
Feb 05
Oversold Korean biotech set to rebound.
Eli Lilly's earnings surprise sharply reversed biotech sentiment. Combined with government support for KOSDAQ and a rotation out of semiconductors, money is returning to Korean biotech. He specifically cited Samsung Biologics and Celltrion strength, and said Alteogen, ABL Bio, and Sam Chun Dang Pharm had been oversold enough to rebound; he recommended biotech/KOSDAQ exposure over KOSPI large caps.
HIGH
13:50
Jan 23
Jan 23
Sam Chun Dang leads oral obesity drugs.
Sam Chun Dang Pharm's S-PASS oral formulation of semaglutide can capture the obesity-drug market after semaglutide patents expire. A potential 15 trillion won contract with 90% profit sharing and Korea Investment & Securities' bullish report make it a leader in oral obesity treatments.
MED
00:41
Jan 06
Jan 06
Korean obesity stocks rebound into JPM Healthcare
Novo Nordisk's oral GLP-1 launch in the U.S. and the upcoming JPMorgan Healthcare conference may revive interest in Korean obesity-drug names. Hanmi Pharm, Sam Chun Dang Pharm, Ildong Pharmaceutical, and D&D Pharmatech are cited as related movers.
MED
About Sam Chun Dang Pharm Investor Commentary
Across the available history and selected sources, Buzzberg tracks Sam Chun Dang Pharm across 2 sources: 5 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 56% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 9 total trade ideas tracked. Latest voices: Jang Woo-jin, Lee Kwon-hee, Lee Chang-dae.